Quick Answer
Viridian Therapeutics, Inc.DE reported Earnings Per Share Diluted of $5.31 (loss) per share for the year ending 2023.
- Viridian Therapeutics, Inc.DE showed a decrease of -31.1% in Earnings Per Share Diluted from 2022 to 2023.
- This data is from Viridian Therapeutics, Inc.DE's annual report (Form 10-K), filed with the SEC on February 27, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 4 years of available data (2020 to 2023), Viridian Therapeutics, Inc.DE's Earnings Per Share Diluted has grown by 82.9%.
- Historical annual values: Fiscal year 2023: $5.31 (loss) per share | Fiscal year 2022: $4.05 (loss) per share | Fiscal year 2021: $6.66 (loss) per share | Fiscal year 2020: $31.13 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: